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Introduction
Elevated serum triglycerides, total cholesterol, very low-
density lipoprotein (VLDL) cholesterol, and low-density
lipoprotein (LDL) cholesterol have been reported in the
literature from areas where experience with antiretroviral
drugs has amassed. Up until recently the use of antiretro-
viral drugs in Nigeria on a wide scale was a rarity owing
largely to prohibitive cost, and so experience with its use
was limited. Here we report 3 cases out of 11 followed up
on antiretroviral drugs for a period of 6 months (June to
November 2002) who had a steady rise in serum triglycer-
ide level, as part of the initial 25 trial patients on free
antiretroviral drugs supplied by the Nigerian federal gov-
ernment as a pilot study  an accelerated clinical trial of a
combination of stavudine/lamivudine/nevirapine in the
treatment of people living with HIV-AIDS in Nigeria  at
the University of Benin teaching hospital, one of the des-
ignated centers for the treatment of HIV/AIDS.
Methods
All patients met the study's eligibility criteria and signed
an informed consent form; the study was approved by the
University teaching Hospital's committee on ethics. All
laboratory tests, which included serum amylase, liver
enzymes and bilirubin, triglyceride levels, hemoglobin
levels, complete blood count, and CD4+ cell count, were
done at the teaching hospital's main laboratory, and
blood samples for triglycerides were all obtained in the
fasting state, CD4+ cell count was determined by flow
cytometry. All laboratory tests were repeated at intervals of
4 weeks throughout the duration of the study.
Eligibility Criteria
Inclusion Criteria
1. Older than 15 years of age
2. HIV seropositivity by double enzyme-linked immu-
nosorbent assay (ELISA) or ELISA and Western blot
3. Willingness to give informed consent
4. Willingness to show up for follow-up visits
5. HIV RNA level > 5000 copies/mL
6. CD4+ cell count of 100-400 cells/microliter (mcL)
7. Patient must be antiretroviral-drug-naive
8. Patient must be willing to continue therapy after the
trial
9. Female patient must be willing to use an adequate
and reliable method of contraception
Exclusion Criteria
1. Younger than 15 years of age
2. Pregnant patients or nursing mother
3. Neutrophil count < 1000/mcL
4. Severe liver or renal disease
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5. Patient on rifampicin or rifabutin therapy
Results
Case 1
O.P., a 35-year-old male commercial driver, was enrolled
in the treatment study group with a body weight of 69.5
kg and a body mass index (BMI) of 24 kg/m2 (his height
was 1.70 m). His CD4+ cell count at commencement was
100 cells/mcL and fasting serum triglyceride was 108 mg/
dL. After 8 weeks of therapy, weight was 70.5 kg and
serum triglyceride was 122 mg/dL. At 16 weeks he
weighed 73 kg and triglyceride had risen to 265 mg/dL. At
24 weeks (end of study), he weighed 74.5 kg and serum
triglyceride was 300 mg/dL; CD4+ cell count had risen to
300 cells/mcL. CD4+ cell counts at 4, 8, 12, 16, and 20
weeks, respectively, were 109, 215, 260, 272, and 292
cells/mcL.
Case 2
O.W., a 22-year-old female University student, was com-
menced on treatment with a body weight of 57 kg and a
BMI of 20.4 kg/m2 (her height was 1.67 m). Her CD4+ cell
count was 310 cells/mcL and she had a fasting serum trig-
lyceride of 169 mg/dL. At 8 weeks of therapy she weighed
67.6 kg and the serum triglyceride had risen to 200 mg/dL.
After 12 weeks of therapy, her weight was 71 kg, with a
CD4 + cell count of 482 cells/mcL and serum triglyceride
of 210 mg/dL. At 16 weeks she weighed 71.5 kg and the
triglyceride level was 220 mg/dL. At 24 weeks (end of
study), body weight was 73 kg, CD4+ cell count was 490
cells/mcL, and triglyceride level was 214 mg/dL.CD4+ cell
counts at 4, 8, 12, 16, and 20 weeks, respectively, were,
315, 350, 415, 445, and 460 cells/mcL.
Case 3
O.A., a 44-year-old male commercial driver, was enrolled
in the treatment group with a body weight of 106.5 kg and
a BMI of 34.8 kg/m2 (height of 1.75 m), with CD4+ cell
count of 390 cells/mcL and triglyceride of 147 mg/dL.
After 8 weeks of therapy, body weight was 108 kg and trig-
lyceride level was 240 mg/dL. At 12 weeks, body weight
was 110 kg, CD4+ cell count had risen to 402 cells/mcL
and triglyceride level was 316 mg/dL. At 16 weeks, weight
was 111.5 kg and serum triglyceride was 317 mg/dL. At 24
weeks (end of study), body weight was 111.5 kg, CD4+
cell count was 423 cells/mcL, and serum triglyceride was
448 mg/dL. CD4+ cell counts at 4, 8, 12, 16, and 20 weeks
were, 394, 398, 410, 418, 420 cells/mcL, respectively.
All 3 patients were referred to the endocrinology unit for
evaluation and treatment on account of elevated (> 200
mg/dL) fasting triglyceride level. Essentially all study sub-
jects had serum amylase levels within normal limits
throughout the duration of study.
Discussion
Highly active antiretroviral therapy (HAART) has been
associated with hypertriglyceridemia, lipodystrophy,
hypercholesterolemia, and insulin resistance, a syndrome
referred to variously as HAART-associated morphologic
and metabolic abnormality syndrome (HAMMAS) or
HIV-associated lipodystrophy syndrome. Initially the pro-
tease inhibitors were implicated but it has been reported
with the use of other classes of antiretroviral drugs.[1,2]
All patients in this study were on lamivudine/stavudine/
nevirapine (nucleoside and nonnucleoside reverse tran-
scriptase inhibitors only). The progressive increases in
body mass index and CD4+ cell count were measures of
good response to therapy. The inclusion of nevirapine in
the regimen is noteworthy owing to its widely reported
beneficial effect on blood lipid profile[3-5] by increasing
the HDL cholesterol levels as compared with protease
inhibitors, though this relative advantage was not proven
in a related study involving older subjects,[6] and in
another study, the lipid profile of patients on nevirapine
was worse compared with HAART-naive subjects.[4] This
is not to say that nevirapine is the definite cause of the
deranged triglyceride levels, but to mention curiously that
in drug combinations devoid of a protease inhibitor, lipid
abnormality (raised triglyceride in this case) is being seen.
The possibility exists here that stavudine, a drug associ-
ated with hepatic steatosis,[1] may be the culprit, but to
mention it as a definite cause also would be preliminary.
Patients on stavudine did not fare worse in blood lipid
parameters compared with zidovudine, another nucleo-
side analogue reverse transcriptase inhibitor, in a related
study comparing both in antiretroviral therapy and blood
lipid profile.[7] The exact contribution of stavudine in
deranged lipid profile remains to be proven, but now that
it is regularly a part of HAART prescriptions in Nigeria,
this may be known with time.
It is also pertinent to discuss the possible role of pancrea-
titis, a condition that has a cause-and-effect relationship
with hypertriglyceridemia, particularly in its chronic
forms in which serum amylase levels may be within nor-
mal limits,[8] as was found in our study patients. In
patients who had normal triglyceride levels at the com-
mencement of study and who were never on didanosine,
a drug known to be associated with pancreatitis, and who
were noticed to have elevated triglyceride levels as early as
4 weeks on HAART, it would not be immodest to associate
the rise with the drugs.
The implication of HAART-induced dyslipidemia in cardi-
ovascular terms is a growing cause for concern against the
backdrop of a continuous therapy, even though the risk
remains to be established.[9-11] Certainly more informa-Publish with BioMed Central    and   every 
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tion will be revealed as other lipid parameters are studied
subsequently.
As yet there appears to be no consensus on the use of
hypolipidemic agents in HAART-induced hyperlipidemia,
and further studies are needed to establish this.[9-12] Reg-
ular follow-up, however, is strongly advised, particularly
in subjects with other risk factors for coronary artery dis-
ease.
Conclusion
That dyslipidemia is a known consequence of HAART
should sensitize regular monitoring of triglyceride and
other indices of lipid profile in individuals on HAART,
with a view to instituting therapy as early as possible when
values are found deranged, particularly in those with
other risk factors for coronary artery disease.
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